(IN BRIEF) AstraZeneca and Daiichi Sankyo have secured European Union approval for Enhertu as a tumour-agnostic monotherapy for adults with previously treated HER2-positive IHC 3+ unresectable or metastatic solid tumours who have no satisfactory treatment alternatives. The decision is the … Read the full press release
Posted in Business, European Union, Healthcare, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged ADC, antibody-drug conjugate, AstraZeneca, Benedikt Westphalen, biomarker testing, breast cancer, cancer treatment, CHMP, colorectal cancer, Daiichi Sankyo, Dave Fredrickson, DESTINY-Breast01, DESTINY-CRC02, DESTINY-Lung01, DESTINY-PanTumor02, EMA, Enhertu, Enhertu Approval Brings HER2-Directed Antibody Drug Conjugate Therapy to Broader Solid Tumour Population, European Commission, European Medicines Agency, gastric cancer, HER2 testing, HER2-positive solid tumours, Ken Keller, metastatic cancer, New EU Enhertu Indication Expands Targeted Treatment Options Beyond Individual Tumour Types, non-small cell lung cancer, objective response rate, oncology, Phase II Evidence Supports EU Tumour-Agnostic Approval of Enhertu for HER2-Positive Cancers, precision oncology, targeted therapy, trastuzumab deruxtecan, tumour-agnostic therapy, unresectable cancer
(IN BRIEF) The Institute of Cancer Research, London, has welcomed the US FDA approval of capivasertib for patients with PTEN-deficient advanced prostate cancer, marking the first regulatory approval of the targeted drug in prostate cancer. Capivasertib blocks AKT, a cancer-driving … Read the full press release
Posted in Business, Education, European Union, Healthcare, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged 3D protein structure, abiraterone, advanced cancer, advanced prostate cancer, AKT inhibitor, AKT pathway, AKT1 mutations, Astex Pharmaceuticals, AstraZeneca, breast cancer, cancer cell growth, cancer cell survival, cancer progression, Cancer Research Technology Limited, Cancer Research UK, CAPItello-281 trial, CAPItello-291 trial, capivasertib, Capivasertib Gains First Prostate Cancer Approval Following Decades of ICR-Led AKT Research, Centre for Cancer Drug Discovery, drug discovery, European Union, FDA, FDA Approval of Capivasertib Marks New Targeted Treatment Option for Advanced Prostate Cancer, fragment-based drug design, fulvestrant, HER2-negative breast cancer, HR-Positive Breast Cancer, ICR, ICR Welcomes FDA Approval of Capivasertib for PTEN-Deficient Advanced Prostate Cancer, ICR Welcomes Milestone FDA Decision for Targeted Therapy in PTEN-Deficient Prostate Cancer, Nature Communications, Nice, oncology research, overall survival, Phase III Trial, PI3 kinase pathway, PIK3CA mutations, precision oncology, Professor Kristian Helin, Professor Paul Workman, prostate cancer patients, prostate cancer treatment, PTEN-deficient prostate cancer, PTEN-deficient tumours, regulatory approval, small molecule inhibitors, targeted therapy, The Institute of Cancer Research, United Kingdom
(IN BRIEF) The University of Warwick-coordinated OPTIMA trial, sponsored by University College London, has found that the Prosigna genomic test could help many patients with early-stage hormone-sensitive breast cancer avoid unnecessary chemotherapy without compromising outcomes. The trial followed more than … Read the full press release
Posted in Education, Healthcare, Pharma & Biotech, Science, United Kingdom
Tagged Adrienne Morgan, American Society of Clinical Oncology, ASCO Annual Meeting, breast cancer, breast oncology, cancer recurrence, cancer research, Cardiff, chemotherapy, clinical trial, early stage breast cancer, gene test, genomic test, hormone therapy, hormone-sensitive breast cancer, Independent Cancer Patients’ Voice, Karen Bonham, lymph nodes, Major OPTIMA Trial Results Could Support Wider NHS Use of Genomic Testing to Reduce Chemotherapy Overtreatment, National Institute for Health and Care Research, NHS, NHS laboratories, Nice, NIHR, OPTIMA trial, Patient and Public Involvement, patient outcomes, personalised treatment, Professor Janet Dunn, Professor Rob Stein, Prosigna, radiotherapy, treatment decision-making, tumour biology, UCL, UCL Cancer Institute, University College London, University of Warwick, University of Warwick and UCL-Led Breast Cancer Trial Highlights Potential to Spare Thousands from Chemotherapy, University of Warwick-Coordinated OPTIMA Trial Shows Genomic Test Could Help Breast Cancer Patients Avoid Unnecessary Chemotherapy, unnecessary chemotherapy, Veracyte Inc, Warwick Clinical Trials Unit
(IN BRIEF) Researchers from The Institute of Cancer Research and The University of Manchester have created the most comprehensive map of cancer-related genetic mutations to date, analysing data from nearly 11,000 patients in the 100,000 Genomes Project. The study identified … Read the full press release
Posted in Education, Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged 100000 Genomes Project, bowel cancer, breast cancer, cancer genomics, David Wedge, DNA mutations, Genomics England, homologous recombination deficiency, HRD, Institute of Cancer Research London, Landmark Study Advances Precision Oncology with Comprehensive Mapping of Cancer-Causing Genetic Mutations, Major Cancer Genomics Study Uncovers New Mutation Signatures Expanding Potential for Precision Treatments, microbiome, mutational signatures, oncology research, ovarian cancer, PARP inhibitors, precision medicine, Richard Houlston, University of Manchester
(IN BRIEF) Researchers from the Luxembourg Institute of Health, together with LISER and STM, have published a new study in BMC Women’s Health analysing the socioeconomic and clinical factors that influence women’s return to work after breast cancer diagnosis based … Read the full press release
Posted in Business, Education, Financial, Healthcare, Industrial, Investment, Luxembourg, Management, Science, Technology
Tagged BMC Women’s Health, breast cancer, Dr Claudine Backes, health inequalities, LIH, LIH Study Highlights Key Factors Shaping Return to Work for Women after Breast Cancer in Luxembourg, LISER, Luxembourg Institute of Health, National Cancer Plan, occupational health, Patient and Public Involvement, PPI, RELIANCE study, return to work, Service de santé au travail multisectoriel, STM, workforce reintegration
(IN BRIEF) A new global analysis by The Institute of Cancer Research (ICR), London, has found that cancer incidence is rising in both younger and older adults, disputing the idea that the global increase is limited to those under 50. … Read the full press release
Posted in Education, Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Annals of Internal Medicine, bowel cancer, breast cancer, cancer incidence, Cancer Prevention, early-onset cancer, endometrial cancer, epidemiology, Global analysis from ICR challenges belief that cancer surge affects only younger adults, Global study, global trends, GLOBOCAN, IARC, ICR, International Agency for Research on Cancer, kidney cancer, leukaemia, Obesity, Older Adults, Professor Amy Berrington, Professor Kristian Helin, public health, screening, The Institute of Cancer Research London, The Institute of Cancer Research study finds cancer rates rising among both younger and older adults worldwide, thyroid cancer, World Health Organization, younger adults
Rebrand: Myeloid Therapeutics becomes CREATE Medicines, reflecting a shift to multi-lineage RNA immune programming. Scientific Focus: Expanding beyond myeloid cells to include T and NK cells for scalable, redosable in vivo CAR therapies. Clinical Data: Over 40 patients treated with … Read the full press release
Posted in Business, Healthcare, Pharma & Biotech, Science, Technology
Tagged 8VC, ARCH Venture Partners, autoimmunity, B-cell depletion, biopsies, Biotech, biotechnology, breast cancer, cancer therapy, CAR+ immune cells, CD8 T cell recruitment, clinical trials, CREATE Medicines, CREATE Medicines Bridges Science Strategy and Investment with Expanded RNA Platform for In Vivo Multi-Immune Therapies in Europe and Beyond, CREATE Medicines Integrates Scientific Progress and Investor Backing to Lead Multi-Lineage RNA Immunotherapy’s Next Chapter in Europe, CREATE Medicines Rebrand Reflects Strategic Expansion into Multi-Lineage RNA Immunotherapy as Europe’s Biotech Sector Embraces In Vivo Therapies, CREATE Medicines Reinforces Its Market and Research Focus Through RNA-Driven Multi-Lineage Immune Programming Amid Rising European Investment in mRNA Therapeutics, CREATE Medicines Strengthens Its Scientific and Strategic Position with Multi-Lineage RNA Platform and Investor Support Across a Growing European Biotech Market, CREATE Medicines’ New Identity Combines RNA-Based Scientific Leadership and Investor Momentum with Expanding Opportunities in European Immunotherapy Markets, CREATE Medicines’ Transition Marks New Phase in RNA Immunotherapy Development and Strategic Growth in Europe’s Expanding Biotech Landscape, Daniel Getts, Daniel Getts Ph.D., fibrosis, Following Its Rebrand, From Myeloid Therapeutics to CREATE Medicines: A Rebrand Uniting RNA Innovation Investor Confidence and Expanding European Immunotherapy Ambitions, GPC3, GPC3-positive solid tumors, GPC3; hepatocellular carcinoma, Hatteras Venture Partners, HER2, HER2 multi-immune CAR, HER2; solid tumors, himeric antigen receptor, immune cell reprogramming, immune cells, immune remodeling, immunotherapies, immunotherapy, in vivo CAR, in vivo CAR-T mediated B cell depletion, in vivo multi-immune programming, mRNA, mRNA-LNP platform, MT-302, MT-303, MT-304, multi-immune programming, multilineage immune programming, myeloid, myeloid cells, Myeloid Therapeutics, myeloid-focused in vivo programming, Newpath Partners, NK cell programming, NK cells, off-the-shelf therapies, oncology, Phase 1 studies, Rebranded CREATE Medicines Aligns Scientific Innovation and Investor Backing to Advance RNA-Based In Vivo CAR Therapies in Global and European Markets, Rebranded CREATE Medicines Positions Itself at the Forefront of RNA Immunotherapy as Europe’s Biotech Ecosystem Accelerates Innovation, retrotransposon-based CAR-T, RNA retrotransposon, RNA technology, RNA-based in vivo CAR therapeutics, RNA-based therapeutics, solid tumors, T cells, therapies, TROP2, TROP2; solid tumors, tumors, vivo CAR, vivo CAR-T
CREATE Medicines (“CREATE”) broadens clinical programs and capabilities to expand therapeutic potential and improve patient outcomes Therapies tolerably program immune cells inside the human body, providing clear differentiation among competitors and significant value potential for all stakeholders CREATE Medicines will … Read the full press release
Posted in Business, Healthcare, Pharma & Biotech, Science, Technology
Tagged 8VC, ARCH Venture Partners, autoimmunity, B-cell depletion, biopsies, Biotech, biotechnology, breast cancer, cancer therapy, CAR+ immune cells, CD8 T cell recruitment, clinical trials, CREATE Medicines, Daniel Getts, Daniel Getts Ph.D., fibrosis, GPC3, GPC3-positive solid tumors, GPC3; hepatocellular carcinoma, Hatteras Venture Partners, HER2, HER2 multi-immune CAR, HER2; solid tumors, immune cell reprogramming, immune cells, immune remodeling, immunotherapies, immunotherapy, in vivo CAR, in vivo CAR-T mediated B cell depletion, in vivo multi-immune programming, mRNA, mRNA-LNP platform, MT-302, MT-303, MT-304, multi-immune programming, multilineage immune programming, myeloid, myeloid cells, Myeloid Therapeutics, myeloid-focused in vivo programming, Newpath Partners, NK cell programming, NK cells, off-the-shelf therapies, oncology, Phase 1 studies, retrotransposon-based CAR-T, RNA retrotransposon, RNA technology, RNA-based in vivo CAR therapeutics, RNA-based therapeutics, solid tumors, T cells, therapies, TROP2, TROP2; solid tumors, tumors, vivo CAR, vivo CAR-T
(IN BRIEF) Researchers at The Institute of Cancer Research and Queen Mary University have created EIRAs, a computational assay that predicts how bowel cancer cells evolve resistance to chemotherapy. By monitoring cell populations and applying evolutionary models, the tool differentiates … Read the full press release
Posted in Business, Education, Financial, Healthcare, Industrial, Investment, Management, Marketing, News, Science, Technology, United Kingdom
Tagged bowel cancer, breast cancer, Cancer Research UK, chemotherapy resistance, colorectal cancer, drug discovery, EIRAs, evolutionary biology, Evolutionary Informed Resistance Assays, Freddie Whiting, genetic mutation, Kristian Helin, Machine Learning, Nature Communications, non-genetic adaptation, ovarian cancer, patent, personalized therapy, Queen Mary University of London, Richard Nichols, The Institute of Cancer Research London, Trevor Graham, Wellcome Trust
(IN BRIEF) The University of Copenhagen, in collaboration with Rigshospitalet, has introduced a clinically validated gene-editing method to identify harmful inherited mutations that raise cancer risk. Developed at the university’s Biotech Research and Innovation Center, the CRISPR-Select technique allows scientists … Read the full press release
Posted in Denmark, Education, Healthcare, News, Pharma & Biotech, Science, Technology
Tagged BRCA2, breast cancer, BRIC, cancer diagnosis, cancer risk, CRISPR-Select, gene editing, genetic testing, genomic medicine, hereditary cancer, Maria Rossing, ovarian cancer, personalized medicine, Rigshospitalet, The Journal of Clinical Investigation, University of Copenhagen, variant classification
(IN BRIEF) A study by the University of Helsinki has uncovered why some breast cancer treatments, including immunotherapy, may not be effective for all patients. The research, focusing on the mechanical properties of tumor tissue, shows that softer tissue environments … Read the full press release
Posted in Business, Education, Financial, Finland, Healthcare, Industrial, Investment, Management, News, Science, Technology
Tagged breast cancer, cancer research, cancer treatment, Finland, global research collaboration, HUS Helsinki University Hospital, immunotherapy, Kymenlaakso Health, MD-PhD student Aino Peura, Nature Communications, personalized medicine, tissue microenvironment, tumor progression, University of Helsinki
(IN BRIEF) A landmark international study has provided robust evidence that elevated levels of prolactin, a hormone involved in breast development, increase the risk of breast cancer in post-menopausal women. Researchers from The Institute of Cancer Research in London, along … Read the full press release
Posted in Business, Education, Financial, Healthcare, Industrial, Investment, Management, News, Science, Technology, United Kingdom
Tagged B2Risk consortium, BMI, breast cancer, Breast Cancer Now, cohort studies, Dr Simon Vincent, early diagnosis, ICR, Institute of Cancer Research, invasive breast cancer, mammographic density, personalized prevention, plasma levels, PMH, polygenic risk score, post-menopausal, Professor Montse Garcia-Closas, prolactin, risk factor, targeted interventions
(IN BRIEF) Researchers have made a significant breakthrough in cancer drug discovery by identifying a new binding site on the eukaryotic initiation factor 4E (eIF4E), a protein long considered undruggable. The collaborative study between The Institute of Cancer Research (ICR) … Read the full press release
Posted in Healthcare, Pharma & Biotech, Science, Technology, United Kingdom
Tagged anticancer therapies, Astex Pharmaceuticals, breast cancer, Cancer Drug Discovery, Cancer Research UK, cancer treatment, Centre for Cancer Drug Discovery, drug development, druggable binding sites, eIF4E, eIF4G, fragment-based screening, ICR, Institute of Cancer Research, Nature Communications, new drug targets, Olivia Rossanese, Paul Clarke, prostate cancer, protein degradation, protein synthesis, protein synthesis regulation, small molecule inhibitors, therapeutic innovation, undruggable protein
(IN BRIEF) Researchers from The Institute of Cancer Research, London, and Barts Cancer Institute have discovered how the extracellular matrix (ECM) surrounding tumours influences cancer cells to become aggressive and spread throughout the body. Their study, published in Nature Communications, … Read the full press release
Posted in Business, Education, Financial, Healthcare, Industrial, Investment, Management, News, Science, Technology, United Kingdom
Tagged Barts Cancer Institute, breast cancer, cancer metastasis, cancer research, Cancer Therapies, cancer treatment, early cancer detection, ECM, extracellular matrix, ICR, lysyl oxidase, melanoma, metastasis, metastasis prevention, Nature Communications, tumor behavior, tumor biology
(IN BRIEF) Roche has announced that the FDA has expanded the approval of its PATHWAY® HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test to identify HER2-ultralow status in HR-positive, HER2-negative metastatic breast cancer patients. This new approval offers a potential treatment … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Switzerland, Technology
Tagged breast cancer, DESTINY-Breast06 trial, diagnostic solutions, Enhertu, FDA, FDA approval, HER2-Low, HER2-targeted therapy, HER2-Ultralow, HR-positive, metastatic breast cancer, PATHWAY HER2, Personalized Treatment, Roche, treatment options
(IN BRIEF) In early 2024, Europe’s medical and research communities announced major breakthroughs in cancer care, highlighting new treatments like AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan for lung and breast cancer, and AstraZeneca’s Tagrisso for EGFR-mutated lung cancer. Diagnostic advancements … Read the full press release
Posted in Finland, Germany, Healthcare, Insurance, News, Pharma & Biotech, Science, Society, Switzerland, Technology, United Kingdom
Tagged accessible cancer solutions, AstraZeneca, Aviva, BioNTech, breast cancer, breast cancer screening, cancer care, cancer diagnostics, cancer prevention awareness, cancer research, cancer treatment, colorectal cancer, Daiichi Sankyo, datopotamab deruxtecan, Duality Biologics, Eckert & Ziegler, EMA, FDA, genetic risk information, Inspirna, lung cancer, Merck KGaA, multi-cancer early detection, neuroendocrine neoplasms diagnostics, Novartis, ompenaclid, oncology, polygenic risk score, preventive healthcare, Professor Tim Maughan, ReSisTrace methodology, Stage III EGFR-mutated lung cancer, Swiss Re Institute, Tagrisso, treatment-resistant cancer cells, University of Helsinki, University of Liverpool
(IN BRIEF) A recent genetic study conducted by researchers at the University of Helsinki suggests that genetic risk information could revolutionize breast cancer screening, potentially benefiting one in ten women. The study indicates that a comprehensive genetic risk profile could … Read the full press release
Posted in Business, Education, Financial, Finland, Healthcare, Industrial, Investment, Management, News, Science, Technology
Tagged breast cancer, Dr. Nina Mars, Genetic Study, Samuli Ripatti, screening, University of Helsinki
(IN BRIEF) Roche has released positive long-term follow-up data from the Phase III KATHERINE study, evaluating Kadcyla® (trastuzumab emtansine) as adjuvant therapy for people with HER2-positive early-stage breast cancer (eBC) who have residual invasive disease following neoadjuvant treatment. The study … Read the full press release
Posted in Business, Healthcare, Industrial, Management, News, Science, Switzerland, Technology
Tagged breast cancer, HER2-Positive, Kadcyla, Levi Garraway, Long-Term Survival, Phase III KATHERINE, Prof. Dr. Sibylle Loibl, Roche
(IN BRIEF) AstraZeneca has unveiled data from four pivotal Phase III trials at the European Society for Medical Oncology (ESMO) Congress, demonstrating advances in cancer treatments across multiple types of cancers. These trials include TROPION-Lung01 and TROPION-Breast01, showcasing the significance … Read the full press release
Posted in Business, Education, Healthcare, Industrial, Management, Media, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged AstraZeneca, breast cancer, cancer treatments, datopotamab deruxtecan, Dave Fredrickson, DESTINY-PanTumor02, DUO-E, ESMO Congress, FLAURA2, gastrointestinal cancer, Imfinzi, lung cancer, MATTERHORN, Phase III Trials, Susan Galbraith, Tagrisso, TROPION-Breast01, TROPION-Lung01
(IN BRIEF) GlaxoSmithKline (GSK) has announced a confidential settlement in the Cantlay/Harper case filed in California state court, which was scheduled for trial in November 2023. Additionally, GSK has settled the three remaining breast cancer bellwether cases in California, effectively … Read the full press release
Posted in Business, Government, Healthcare, Industrial, Law, Management, News, Pharma & Biotech, Science, United Kingdom
Tagged breast cancer, California, Confidential Settlements, GSK, litigation, Zantac
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?